Aligos Therapeutics Inc(股票代码:ALGS)宣布,其研发的慢性乙型肝炎治疗药物Pevifoscorvir Sodium已获得美国食品药品监督管理局(FDA)授予的快速通道资格认定。这一认定将加速该药物的审评进程,有望为慢性乙肝患者提供新的治疗选择。
Aligos Therapeutics Inc(股票代码:ALGS)宣布,其研发的慢性乙型肝炎治疗药物Pevifoscorvir Sodium已获得美国食品药品监督管理局(FDA)授予的快速通道资格认定。这一认定将加速该药物的审评进程,有望为慢性乙肝患者提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.